chb

Vebicorvir (ABI-H0731), a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity.

CHBO4 is an hMAO-B inhibitor that is potent, reversible, competitive and selective.The IC50 value of CHBO4 against hMAO-B in the CHBO assay was 0.031 μM, and the Ki value was 0.010 ± 0.005 μM.CHBO4 reduces cellular damage by scavenging intracellular reactive oxygen species (ROS), and can be used to study Parkinson's disease (PD).

(E)-CHBO4 is an MAO-B inhibitor with an IC50 value of 0.023 μM, making it a potential candidate for research into Parkinson's disease treatment.

Thioether-cyclized helix B peptide (CHBP) enhances metabolic stability and exerts renoprotective effects by promoting autophagy through the inhibition of mTOR C1 and activation of mTOR C2 [1].

Thioether-cyclized helix B peptide, CHBP (TFA), is the trifluoroacetic (TFA) salt of CHBP, enhancing metabolic stability and exhibiting renoprotective effects by promoting autophagy through inhibition of mTOR C1 and activation of mTOR C2 [1].

MCHB-1, a potent agonist of the human cannabinoid 2 (CB2) receptor (EC50= 0.52 nM), demonstrates high selectivity for CB2 over CB1 (Kis = 3.7 and 110 nM, respectively), distinguishing itself from similar benzimidazole compounds that significantly alleviate peripheral pain while minimizing central nervous system side effects in mice.

Kanamycin sulfate (Kanamycin monosulfate) is an aminoglycoside antibiotic that interferes with protein synthesis by binding to the 70S ribosomal subunit of bacteria. Kanamycin sulfate exhibits antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as mycoplasmas.

PROTACHBeAg degrader-1 is a PROTAC-based targeted degrader of HBeAg. It effectively recruits the VHL E3 ligase, yet its ability to degrade the hepatitis B virus protein (HBeAg) does not depend on VHL recruitment. This compound decreases levels of both secreted and intracellular HBeAg and is suitable for research involving the hepatitis B virus (HBV).

Schisandrin B (Schisandrin B (Sch B)) has an antioxidant effect on rodent liver and heart.

Tenofovir amibufenamide (HS-10234) is a Tenofovir prodrug, an antiviral compound with oral activity. Tenofovir amibufenamide inhibits hepatitis B virus (HBV) and can be used in chronic hepatitis B (CHB) studies.

Besifovir Dipivoxil (LB80380) maleate is an oral prodrug of LB80317. Besifovir Dipivoxil maleate is effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients.

HBV-IN-52 is a selective inhibitor of HBV and a derivative of Neplanocin A, displaying significant anti-hepatitis B virus replication activity with an EC50 of 0.96 μM. It also suppresses the secretion of hepatitis B surface antigen (HBsAg) with an EC50 of 0.82 μM. HBV-IN-52 is useful for studying chronic hepatitis B (CHB) infection.

DF-006 is an innovative orally active agonist of ALPK1 (α-kinase 1). It stimulates the innate immune response in the liver by activating the NF-κB pathway. DF-006 effectively reduces serum levels of hepatitis B virus (HBV) DNA (EC50 = 2.7 pM), HBsAg, and HBeAg, demonstrating potent antiviral activity, making it suitable for immunotherapy research in chronic hepatitis B (CHB).

ALG-001075, a capsid assembly modulator (CAM), is an orally active inhibitor of HBV. It effectively suppresses HBV DNA production in primary human hepatocytes and significantly reduces extracellular levels of HBsAg/HBeAg and intracellular HBV RNA. In AAV-HBV mouse models, ALG-001075 notably decreases HBV DNA levels. It can be utilized in research related to chronic hepatitis B (CHB).

Cinobufotalin is a main cardiac toxin in toad, it is a novel anti-HCC agent, it induces growth inhibition and apoptosis in cultured HCC cells through ceramide production. Cinobufotalin is also an effective reversal agent for the multidrug resistance of tu

AB-506 is a compound that serves as an orally administered inhibitor specifically targeting the hepatitis B virus (HBV) core protein to obstruct HBV replication. It achieves this by binding to the HBV core protein, accelerating capsid assembly, and hindering the encapsidation of HBV pre-genomic RNA (pgRNA). Consequently, AB-506 is utilized in the study of chronic hepatitis B (CHB).

HBV-IN-47 (compound 4a) functions as a capsid assembly modulator with activity against the hepatitis B virus (HBV). It exhibits potent anti-HBV activity in HepAD38 cells and has low toxicity (EC50=0.24 μM). This compound is applicable for research into chronic hepatitis B (CHB).

Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody that targets hepatitis B surface antigen (HBsAg). It exhibits significant antiviral activity by neutralizing and clearing HBV and HDV, as well as eliminating subviral particles containing HBsAg. Brelovitug is applicable for research on HDV and HBV infections, chronic hepatitis D (CHD), and chronic hepatitis B (CHB).